Labcorp to Acquire Myriad’s Vectra Testing Business for $150M

 Labcorp to Acquire Myriad’s Vectra Testing Business for $150M


  • Labcorp acquires the Vectra RA test from Myriad Genetics along with other operating assets and IP for $150M in cash. The transaction is expected to close in Q3’21
  • The divestiture of Myriad auto immune’s Vectra testing business allow Labcorb to bolster its rheumatology and autoimmune portfolios
  • Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It has been used by ~1M patients to understand their RA disease activity

Click here to­ read full press release/ article | Ref: Businesswire | Image: Wikipedia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post